Novartis's Latest Trial Setback Sinks Stock
Novartis shares fell 10% after its experimental neuromuscular drug, del-desiran, failed to meet the primary goal in a late-stage trial. This is the second trial failure in a week for the company, raising concerns about its growth prospects. Novartis acquired del-desiran through its $12 billion purchase of Avidity Biosciences in February. The company reiterated its sales growth guidance for 2025-30.
How this was made
The 30-second read
Why it matters
The trial failure undermines the growth narrative tied to the Avidity deal and may delay revenue expectations.
Market read
First report of a major trial miss causing a 10% stock drop; traders should consider short positions.
What to watch
Novartis still has other pipeline assets and a recent $12 bn acquisition that may cushion earnings.
Background
Novartis recently completed a $12 bn acquisition of Avidity Biosciences, adding del‑desiran to its pipeline.
Ticker impact
Novartis shares fell 10% after its late‑stage trial of del‑desiran missed the primary endpoint.
Further downside pressure; potential intraday move to 150‑155 CHF.
First disclosure of a pivotal trial failure for a major pipeline asset, causing a sharp sell‑off.
Market effects
Biotech and neuromuscular therapy sector may see broader risk reassessment.
European pharma stocks could face short‑term pressure.
Limited to biotech investors; no broad market impact.
Counterpoint
If the company can pivot del‑desiran to other indications, the sell‑off may be overblown.
Key entities
- CompanyNovartis AG
Swiss multinational pharmaceutical firm.
- Drug Candidatedel‑desiran
Antibody‑oligonucleotide conjugate for myotonic dystrophy type 1.
